- Home
- CFFI vs NERV Comparison
CFFI vs NERV Comparison
Compare CFFI & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CFFI | NERV |
|---|---|---|
| Founded | 1927 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.7M | 207.7M |
| IPO Year | 1998 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CFFI | NERV |
|---|---|---|
| Price | $77.92 | $6.32 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 3.9K | ★ 100.8K |
| Earning Date | 01-27-2026 | 02-23-2026 |
| Dividend Yield | ★ 2.36% | N/A |
| EPS Growth | ★ 38.69 | N/A |
| EPS | ★ 8.34 | N/A |
| Revenue | ★ $129,291,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.35 | ★ N/A |
| Revenue Growth | ★ 13.43 | N/A |
| 52 Week Low | $53.14 | $1.15 |
| 52 Week High | $86.58 | $12.46 |
Technical Indicators
Market Signals| Indicator | CFFI | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 58.65 | 71.54 |
| Support Level | $77.09 | $4.13 |
| Resistance Level | $78.86 | $6.47 |
| Average True Range (ATR) | 1.50 | 0.54 |
| MACD | 0.14 | 0.21 |
| Stochastic Oscillator | 71.04 | 92.05 |
Price Performance
Historical ComparisonAbout CFFI C&F Financial Corporation
C&F Financial Corp is an American bank holding company. The company through its subsidiaries offers banking and related financial services to both individuals and businesses. It operates in three business activities: Community Banking, Mortgage Banking, and Consumer Finance. It mainly provides a range of lending activities, which include residential mortgage loans, commercial real estate loans, non-prime automobile lending, land acquisition, and development loans, and consumer loans. The company generates maximum of its revenue from the Community Banking segment.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.